These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 23474639)

  • 1. Monte Carlo-based 3-dimensional dosimetry of salivary glands in radioiodine treatment of differentiated thyroid cancer estimated using 124I PET.
    Hobbs RF; Jentzen W; Bockisch A; Sgouros G
    Q J Nucl Med Mol Imaging; 2013 Mar; 57(1):79-91. PubMed ID: 23474639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of saliva flow stimulation on the absorbed radiation dose to the salivary glands during radioiodine therapy of thyroid cancer using 124I PET(/CT) imaging.
    Jentzen W; Balschuweit D; Schmitz J; Freudenberg L; Eising E; Hilbel T; Bockisch A; Stahl A
    Eur J Nucl Med Mol Imaging; 2010 Dec; 37(12):2298-306. PubMed ID: 20625723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iodine kinetics and dosimetry in the salivary glands during repeated courses of radioiodine therapy for thyroid cancer.
    Liu B; Huang R; Kuang A; Zhao Z; Zeng Y; Wang J; Tian R
    Med Phys; 2011 Oct; 38(10):5412-9. PubMed ID: 21992360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-therapeutic (124)I PET(/CT) dosimetry confirms low average absorbed doses per administered (131)I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancer.
    Jentzen W; Hobbs RF; Stahl A; Knust J; Sgouros G; Bockisch A
    Eur J Nucl Med Mol Imaging; 2010 May; 37(5):884-95. PubMed ID: 20069293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between cumulative radiation dose and salivary gland uptake associated with radioiodine therapy of thyroid cancer.
    Jentzen W; Schneider E; Freudenberg L; Eising EG; Görges R; Müller SP; Brandau W; Bockisch A
    Nucl Med Commun; 2006 Aug; 27(8):669-76. PubMed ID: 16829767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-Response Relationship in Differentiated Thyroid Cancer Patients Undergoing Radioiodine Treatment Assessed by Means of 124I PET/CT.
    Wierts R; Brans B; Havekes B; Kemerink GJ; Halders SG; Schaper NN; Backes WH; Mottaghy FM; Jentzen W
    J Nucl Med; 2016 Jul; 57(7):1027-32. PubMed ID: 26917706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. I-124 PET/CT image-based dosimetry in patients with differentiated thyroid cancer treated with I-131: correlation of patient-specific lesional dosimetry to treatment response.
    Plyku D; Hobbs RF; Wu D; Garcia C; Sgouros G; Van Nostrand D
    Ann Nucl Med; 2022 Mar; 36(3):213-223. PubMed ID: 35119623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Three-dimensional radiobiological dosimetry (3D-RD) with 124I PET for 131I therapy of thyroid cancer.
    Sgouros G; Hobbs RF; Atkins FB; Van Nostrand D; Ladenson PW; Wahl RL
    Eur J Nucl Med Mol Imaging; 2011 May; 38 Suppl 1(Suppl 1):S41-7. PubMed ID: 21484384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Whole-remnant and maximum-voxel SPECT/CT dosimetry in
    Mínguez P; Flux G; Genollá J; Delgado A; Rodeño E; Sjögreen Gleisner K
    Med Phys; 2016 Oct; 43(10):5279-5287. PubMed ID: 28105713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of lesion response in the initial radioiodine treatment of differentiated thyroid cancer using 124I PET imaging.
    Jentzen W; Hoppenbrouwers J; van Leeuwen P; van der Velden D; van de Kolk R; Poeppel TD; Nagarajah J; Brandau W; Bockisch A; Rosenbaum-Krumme S
    J Nucl Med; 2014 Nov; 55(11):1759-65. PubMed ID: 25332440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases.
    Song H; He B; Prideaux A; Du Y; Frey E; Kasecamp W; Ladenson PW; Wahl RL; Sgouros G
    J Nucl Med; 2006 Dec; 47(12):1985-94. PubMed ID: 17138741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discrepant salivary gland response after radioiodine and MIBG therapies.
    Jentzen W; Richter M; Poeppel TD; Schmitz J; Brandau W; Bockisch A; Binse I
    Q J Nucl Med Mol Imaging; 2017 Sep; 61(3):331-339. PubMed ID: 25566809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High Level of Agreement Between Pretherapeutic 124I PET and Intratherapeutic 131I Imaging in Detecting Iodine-Positive Thyroid Cancer Metastases.
    Ruhlmann M; Jentzen W; Ruhlmann V; Pettinato C; Rossi G; Binse I; Bockisch A; Rosenbaum-Krumme S
    J Nucl Med; 2016 Sep; 57(9):1339-42. PubMed ID: 27151981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET.
    Eschmann SM; Reischl G; Bilger K; Kupferschläger J; Thelen MH; Dohmen BM; Besenfelder H; Bares R
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):760-7. PubMed ID: 12029549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software.
    Sgouros G; Kolbert KS; Sheikh A; Pentlow KS; Mun EF; Barth A; Robbins RJ; Larson SM
    J Nucl Med; 2004 Aug; 45(8):1366-72. PubMed ID: 15299063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantification of salivary gland function in thyroid cancer patients treated with radioiodine.
    Malpani BL; Samuel AM; Ray S
    Int J Radiat Oncol Biol Phys; 1996 Jun; 35(3):535-40. PubMed ID: 8655377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radioprotection of salivary glands by amifostine in high-dose radioiodine treatment. Results of a double-blinded, placebo-controlled study in patients with differentiated thyroid cancer.
    Bohuslavizki KH; Klutmann S; Brenner W; Kröger S; Buchert R; Bleckmann C; Mester J; Henze E; Clausen M
    Strahlenther Onkol; 1999 Nov; 175 Suppl 4():6-12. PubMed ID: 10584133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acquisition settings for PET of 124I administered simultaneously with therapeutic amounts of 131I.
    Lubberink M; van Schie A; de Jong HW; van Dongen GA; Teule GJ
    J Nucl Med; 2006 Aug; 47(8):1375-81. PubMed ID: 16883019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-specific dosimetry using pretherapy [¹²⁴I]m-iodobenzylguanidine ([¹²⁴I]mIBG) dynamic PET/CT imaging before [¹³¹I]mIBG targeted radionuclide therapy for neuroblastoma.
    Huang SY; Bolch WE; Lee C; Van Brocklin HF; Pampaloni MH; Hawkins RA; Sznewajs A; DuBois SG; Matthay KK; Seo Y
    Mol Imaging Biol; 2015 Apr; 17(2):284-94. PubMed ID: 25145966
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Pistone D; Gnesin S; Auditore L; Italiano A; Cascini GL; Amato E; Cicone F
    Phys Med Biol; 2023 Apr; 68(8):. PubMed ID: 36944252
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.